- Home
- TSBK vs CLLS Comparison
TSBK vs CLLS Comparison
Compare TSBK & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TSBK | CLLS |
|---|---|---|
| Founded | 1915 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 306.8M | 374.2M |
| IPO Year | 1997 | 2014 |
Fundamental Metrics
Financial Performance| Metric | TSBK | CLLS |
|---|---|---|
| Price | $38.03 | $4.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 15.6K | ★ 32.5K |
| Earning Date | 04-28-2026 | 01-01-0001 |
| Dividend Yield | ★ 2.97% | N/A |
| EPS Growth | ★ 21.93 | N/A |
| EPS | ★ 1.04 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $32.58 |
| Revenue Next Year | N/A | $20.68 |
| P/E Ratio | $37.53 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $27.51 | $1.10 |
| 52 Week High | $40.41 | $5.48 |
Technical Indicators
Market Signals| Indicator | TSBK | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 49.16 | 50.21 |
| Support Level | $30.95 | $3.93 |
| Resistance Level | $38.18 | $4.54 |
| Average True Range (ATR) | 0.78 | 0.21 |
| MACD | -0.18 | 0.06 |
| Stochastic Oscillator | 10.64 | 84.00 |
Price Performance
Historical ComparisonAbout TSBK Timberland Bancorp Inc.
Timberland Bancorp Inc is a bank holding company for Timberland Bank. The bank offers banking services including personal checking and savings accounts, debit cards, health savings accounts, online and mobile banking, online bill pay, 24-hour phone banking, and Zelle. Business services include business checking accounts, online banking, remote deposit, ACH transactions, Autobooks, and insured cash sweep services. The bank also provides lending services such as personal credit cards, home loans, home equity borrowing, construction loans, and SBA loans. In addition, it offers loans to real estate, including residential and commercial real estate, multi-family construction loans, one- to four-family residential loans, multi-family loans, commercial real estate loans, and land loans.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.